Abbott MediaRoom (Product) http://abbott.mediaroom.com/ Abbott Initiates Study to Evaluate Ablation as a Frontline Treatment for Patient's Suffering from a Common but Complex Cardiac Arrhythmia http://abbott.mediaroom.com/2018-11-20-Abbott-Initiates-Study-to-Evaluate-Ablation-as-a-Frontline-Treatment-for-Patients-Suffering-from-a-Common-but-Complex-Cardiac-Arrhythmia LESS-VT Study is the first U.S. clinical trial to evaluate the safety and effectiveness of ablation treatment for patients with monomorphic ventricular tachycardia, a common heart rhythm disorder Tue, 20 Nov 2018 09:00:00 -0500 http://abbott.mediaroom.com/2018-11-20-Abbott-Initiates-Study-to-Evaluate-Ablation-as-a-Frontline-Treatment-for-Patients-Suffering-from-a-Common-but-Complex-Cardiac-Arrhythmia New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant http://abbott.mediaroom.com/2018-11-15-New-Approvals-Allow-Chronic-Pain-Sufferers-to-Try-Abbotts-Non-Opioid-Pain-Therapy-Before-Getting-Device-Implant - Neurostimulation of the dorsal root ganglion (DRG) can provide pain relief for patients battling chronic pain when previous treatment options were unsuccessful Thu, 15 Nov 2018 09:00:00 -0500 http://abbott.mediaroom.com/2018-11-15-New-Approvals-Allow-Chronic-Pain-Sufferers-to-Try-Abbotts-Non-Opioid-Pain-Therapy-Before-Getting-Device-Implant Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results http://abbott.mediaroom.com/2018-10-25-Abbott-Introduces-the-Next-Generation-of-Influenza-A-B-and-Strep-A-Assays-with-Fastest-Ever-Time-to-Molecular-Results NEW ASSAYS EMPOWER CLINICIANS TO MORE QUICKLY MAKE THE RIGHT DIAGNOSIS AT THE POINT-OF-CARE AND PRESCRIBE THE RIGHT TREATMENT Thu, 25 Oct 2018 09:00:00 -0400 http://abbott.mediaroom.com/2018-10-25-Abbott-Introduces-the-Next-Generation-of-Influenza-A-B-and-Strep-A-Assays-with-Fastest-Ever-Time-to-Molecular-Results Abbott's HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant http://abbott.mediaroom.com/2018-10-19-Abbotts-HeartMate-3-Heart-Pump-Now-FDA-Approved-for-Advanced-Heart-Failure-Patients-Not-Eligible-for-a-Heart-Transplant - Advanced heart failure patients who will live with their device for the rest of their life now have access to a heart pump backed by the industry's strongest long-term data Fri, 19 Oct 2018 09:00:00 -0400 http://abbott.mediaroom.com/2018-10-19-Abbotts-HeartMate-3-Heart-Pump-Now-FDA-Approved-for-Advanced-Heart-Failure-Patients-Not-Eligible-for-a-Heart-Transplant Abbott′s FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe http://abbott.mediaroom.com/2018-10-01-Abbott-s-FreeStyle-R-Libre-2-with-Optional-Real-Time-Alarms-Secures-CE-Mark-for-Use-in-Europe - New features further enhance Abbott′s market leading sensor-based continuous glucose monitoring technology Mon, 01 Oct 2018 08:00:00 -0400 http://abbott.mediaroom.com/2018-10-01-Abbott-s-FreeStyle-R-Libre-2-with-Optional-Real-Time-Alarms-Secures-CE-Mark-for-Use-in-Europe